Zynex appoints Donald Gregg VP of sales and operations of monitoring solutions division

Zynex appoints Donald Gregg VP of sales and operations of monitoring solutions division

ENGLEWOOD -- Zynex, Inc. (Nasdaq: ZYXI) announced it hired Donald Gregg as VP of sales and operations of its monitoring solutions division. Gregg will lead operations, sales, marketing and... Read More

Wednesday April 21, 2021 0 comments Tags: Englewood, Zynex Medical, Donald Gregg, Thomas Sandgaard

Research shows Ampion mimics anti-inflammatory effects of steroids but without adverse effects

Research shows Ampion mimics anti-inflammatory effects of steroids but without adverse effects

ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced findings of pre-clinical research demonstrating Ampio's lead drug candidate, Ampion, provides some of the same anti-inflammatory... Read More

Tuesday April 20, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Dr. David Bar-Or, Michael Macaluso

Ampio study: Ampion inhibits key inflammatory pathway in COVID-19 and lupus nephritis

Ampio study: Ampion inhibits key inflammatory pathway in COVID-19 and lupus nephritis

ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced results of a pre-clinical study demonstrating Ampion inhibits an important pro-inflammatory pathway in the types of immune cells... Read More

Friday April 9, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19, lupus nephritis, Dr. David Bar-Or

Innospec's new Trident bunker fuel additive packages to improve flow properties and operability of IMO 2020-compliant ULSFO and VLSFO fuels

Innospec's new Trident bunker fuel additive packages to improve flow properties and operability of IMO 2020-compliant ULSFO and VLSFO fuels

ENGLEWOOD -- Innospec Fuel Specialties (IFS), a division of Innospec Inc. (NASDAQ: IOSP), announced the addition of its new Trident bunker fuel additives to the marine and bunker fuel market. ... Read More

Friday April 2, 2021 0 comments Tags: Englewood, Innospec

Ampio Pharmaceuticals details early positive results for inhaled Ampion in COVID-19 distress

Ampio Pharmaceuticals details early positive results for inhaled Ampion in COVID-19 distress

ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) revealed preliminary positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in... Read More

Wednesday March 17, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Inhaled Ampion, COVID-19, Michael Macaluso

Ampio adds new hospitals in trial for inhalation treatment of COVID-19

Ampio adds new hospitals in trial for inhalation treatment of COVID-19

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the addition of two new study sites to further the expansion of its ongoing U.S. Phase I clinical trial for inhalation... Read More

Wednesday February 24, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Mike Macaluso, COVID-19

Paragon 28 adds magnesium based bone void filler to its portfolio

Paragon 28 adds magnesium based bone void filler to its portfolio

ENGLEWOOD -- Paragon 28, Inc. announced the launch of MgNum Bone Void Filler (BVF). MgNum BVF is designed to fill bony voids and defects that are not intrinsic to the stability of the bone... Read More

Wednesday February 17, 2021 0 comments Tags: Englewood, Paragon 28, MgNum Bone Void Filler, Matt Jarboe

Ampio announces early positive data in Phase 1 trial of inhaled Ampion in treating COVID-19 distress

Ampio announces early positive data in Phase 1 trial of inhaled Ampion in treating COVID-19 distress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE American: AMPE) announced early positive data from its ongoing U.S. Phase I controlled, observer-blinded clinical trial of inhaled Ampion versus... Read More

Tuesday February 2, 2021 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19